Boston Scientific recently began enrollment in a new study – the Intracept Minimally-invasive PROcedure for VErtebrogenic back pain (IMPROVE) – to compile real-world outcomes of patients treated with the next-generation Intracept™ Access Instruments.
The IMPROVE Study will strengthen evidence around global and real-world Intracept Procedure outcomes across multiple physician specialties and geographies, building on the strong foundation of existing clinical evidence, including two Level I randomized clinical trials.
Please visit our Clinical Evidence page to learn more about the robust clinical evidence supporting the Intracept Procedure.